CALGB 70604 (Alliance): A randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer

被引：0
|
作者：
Himelstein, Andrew Louis
Qin, Rui
Novotny, Paul J.
Seisler, Drew K.
Khatcheressian, James L.
Roberts, John D.
Grubbs, Stephen S.
O'Connor, Tracey
Weckstein, Douglas
Loprinzi, Charles L.
Shapiro, Charles L.
机构：
[1] Helen F Graham Canc Ctr & Res Inst, Newark, DE USA
[2] Mayo Clin, Alliance Stat & Data Ctr, Rochester, MN USA
[3] Virginia Canc Inst, Richmond, VA USA
[4] Yale Univ, New Haven, CT USA
[5] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
[6] New Hampshire Onc Hem PA, Hooksett, NH USA
[7] Mayo Clin, Rochester, MN USA
[8] Mt Sinai Sch Med, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9501
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Zoledronic Acid Dosing Interval for Metastatic Cancer
    Tucci, Marcello
    Buttigliero, Consuelo
    Di Maio, Massimo
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (14): : 1477 - 1478
  • [2] Zoledronic Acid Dosing Interval for Metastatic Cancer Reply
    Himelstein, Andrew L.
    Loprinzi, Charles L.
    Shapiro, Charles L.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (14): : 1478 - 1478
  • [3] Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases A Randomized Clinical Trial
    Himelstein, Andrew L.
    Foster, Jared C.
    Khatcheressian, James L.
    Roberts, John D.
    Seisler, Drew K.
    Novotny, Paul J.
    Qin, Rui
    Go, Ronald S.
    Grubbs, Stephen S.
    O'Connor, Tracey
    Velasco, Mario R., Jr.
    Weckstein, Douglas
    O'Mara, Ann
    Loprinzi, Charles L.
    Shapiro, Charles L.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (01): : 48 - 58
  • [4] Re: Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients with Bone Metastases: A Randomized Clinical Trial
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2017, 198 (03): : 484 - 484
  • [5] Re: Effect of Longer-interval Versus Standard Dosing of Zoledronic Acid on Skeletal Events in Patients with Bone Metastases
    Parker, Chris
    EUROPEAN UROLOGY, 2018, 73 (02) : 304 - 304
  • [6] Economic evaluation of personalized vs. standard dosing of 5-fluorouracil in first-line chemotherapy for metastatic colorectal cancer in Australia
    Erku, Daniel
    Martin, Jennifer H.
    Michael, Michael
    Galettis, Peter
    Scuffham, Paul
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024,
  • [7] Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4Weeks inWomen With Breast Cancer Metastatic to Bone The OPTIMIZE-2 Randomized Clinical Trial
    Hortobagyi, Gabriel N.
    Van Poznak, Catherine
    Harker, W. Graydon
    Gradishar, William J.
    Chew, Helen
    Dakhil, Shaker R.
    Haley, Barbara B.
    Sauter, Nicholas
    Mohanlal, Ramon
    Zheng, Ming
    Lipton, Allan
    JAMA ONCOLOGY, 2017, 3 (07) : 906 - 912
  • [8] Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer
    Michaelson, M. Dror
    Kaufman, Donald S.
    Kantoff, Philip
    Oh, William K.
    Smith, Matthew R.
    CANCER, 2006, 107 (03) : 530 - 535
  • [9] A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol study
    Gwenaelle Gravis
    Patricia Marino
    Daniel Olive
    Frederique Penault-LLorca
    Jean-Pierre Delord
    Clotilde Simon
    Assia Lamrani-Ghaouti
    Renaud Sabatier
    Joseph Ciccolini
    Jean-Marie Boher
    BMC Cancer, 23
  • [10] A phase III randomized study of misonidazole plus radiation vs. radiation alone for cervix cancer
    Chan, P
    Milosevic, M
    Fyles, A
    Carson, J
    Pintilie, M
    Rauth, M
    Thomas, G
    RADIOTHERAPY AND ONCOLOGY, 2004, 70 (03) : 295 - 299
12345